Kinase inhibition remains an area of significant interest across academia and in the pharmaceutical industry. There are now many marketed drugs which target kinases and a significant number of compounds are currently in various stages of clinical development. Although there have been a number of publications on kinase inhibition, this is the first to examine the future opportunities and challenges in targeting this important family of enzymes. The book is forward-looking and focuses on a number of key areas for kinase inhibition over the coming years.
